Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 388 results found since Jan 2013.
TEMPORARY REMOVAL: Mortality after stroke in patients with paroxysmal chronic atrial fibrillation — The FibStroke study
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Antti Palomäki, Tuomas Kiviniemi, Pirjo Mustonen, Casey Odei, Juha E.K. Hartikainen, Ilpo Nuotio, Antti Ylitalo, Päivi Hartikainen, Fausto Biancari, K.E. Juhani Airaksinen Source Type: research
Preclinical Assessment of a Modified Occlutech Left Atrial Appendage Closure Device in a Canine Model
LAA occlusion has a similar stroke prevention efficacy compared to anticoagulation treatment for non-valvular atrial fibrillation.
Source: International Journal of Cardiology - July 4, 2016 Category: Cardiology Authors: Jung-Sun Kim, Seul-Gee Lee, Sung-Kyung Bong, Se-Il Park, Sung-Yu Hong, Sanghoon Shin, Chi Young Shim, Geu-Ru Hong, Donghoon Choi, Yangsoo Jang, Jai-Wun Park Source Type: research
Atrial Fibrillation and Chronic Kidney Disease Requiring Hemodialysis – Does Warfarin Therapy Improve the Risks of this Lethal Combination?
Warfarin therapy for stroke prevention is recommended for patients with AF, but its value in patients with chronic kidney disease on HD is unknown.
Source: International Journal of Cardiology - July 7, 2016 Category: Cardiology Authors: Lohit Garg, Charity Chen, David E. Haines Source Type: research
The Value of Urine Albumin in Predicting Thromboembolic Events for Patients with Non-valvular Atrial Fibrillation
Accurate risk stratification is important in the management of patients with non-valvular atrial fibrillation (NVAF). However, one cohort study demonstrated an annual ischemic stroke rate of 1.61% in the group of patients classified in “the true low risk” according to CHA2DS2-VASc. We aimed to find out more indicators and evaluate their abilitis in predicting thromboembolic events (TE).
Source: International Journal of Cardiology - July 10, 2016 Category: Cardiology Authors: Haohui He, Jun Guo, Aidong Zhang Source Type: research
Atrial fibrillation and chronic kidney disease requiring hemodialysis — Does warfarin therapy improve the risks of this lethal combination?
Warfarin therapy for stroke prevention is recommended for patients with AF, but its value in patients with chronic kidney disease on HD is unknown.
Source: International Journal of Cardiology - July 7, 2016 Category: Cardiology Authors: Lohit Garg, Charity Chen, David E. Haines Source Type: research
TEMPORARY REMOVAL: Mortality after stroke in patients with paroxysmal chronic atrial fibrillation — The FibStroke study
The publisher regrets that this article has been temporarily removed. A replacement will appear as soon as possible in which the reason for the removal of the article will be specified, or the article will be reinstated.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Antti Palom äki, Tuomas Kiviniemi, Pirjo Mustonen, Casey Odei, Juha E.K. Hartikainen, Ilpo Nuotio, Antti Ylitalo, Päivi Hartikainen, Fausto Biancari, K.E. Juhani Airaksinen Source Type: research
Geographic and socio-demographic differences in uptake of population-based screening for atrial fibrillation: the STROKESTOP 1 study
The rationale behind screening for atrial fibrillation (AF) is to prevent ischemic stroke. Socio-demographic differences are expected to affect screening uptake. Geographic differences may provide further insights leading to targeted interventions for improved uptake. The objevtive of this study was to evaluate geographic and socio-demographic differences in uptake of AF screening in the population-based study STROKESTOP I.
Source: International Journal of Cardiology - July 28, 2016 Category: Cardiology Authors: Johan Engdahl, Anders Holm én, Emma Svennberg, Leif Friberg, Viveka Frykman-Kull, Faris Al-Khalili, Mårten Rosenqvist, Ulf Strömberg Source Type: research
Chronic anticoagulation in non-valvular atrial fibrillation: Where things stand
One in every five strokes is due to atrial fibrillation. Anticoagulation is the evidence-based practice for stroke risk reduction in patients with atrial fibrillation. After decades of using warfarin, the recent years have seen an exponential increase in the available oral anticoagulants. An understanding of where things stand regarding indications, relative safety and efficacy as well as the limitations of each available choice is crucial.
Source: International Journal of Cardiology - August 1, 2016 Category: Cardiology Authors: Kareem Bedeir, Robert P. Giugliano, Basel Ramlawi Tags: Review Source Type: research
Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease
Atrial fibrillation (AF) is the most frequent sustained arrhythmia. Overall prevalence is estimated to 5.5% and the incidence increases with age. As the population ages, the prevalence and costs of AF are expected to increase. AF is the most important cause of stroke in patients>75years. Until recently, Vitamin K antagonists (VKAs) were the only available oral anticoagulants (OACs) evaluated for long-term treatment of patients with AF with or without coronary heart disease (CHD). This situation was challenged by introduction of non-VKA oral anticoagulants (NOACs).
Source: International Journal of Cardiology - August 3, 2016 Category: Cardiology Authors: Xavier Humbert, Vincent Roule, Mathieu Chequel, Sophie Fedrizzi, Marie Brionne, V éronique Lelong-Boulouard, Paul Milliez, Joachim Alexandre Tags: Review Source Type: research
First Case of Percutaneous Left Atrial Appendage Closure by Amulet ™ Device in a Patient with Left Atrial Appendage Thrombus
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a major cause of embolic stroke [1]. Even though there is strong evidence that oral anticoagulation (OAC) is highly effective in preventing thromboembolism in patients with AF, as many as 40% of eligible patients do not receive OAC because of contraindications or high bleeding risk [2]. Transesophageal echocardiography (TEE) data and surgical reports have confirmed that>90% of AF-related thrombi originate from the left atrial appendage (LAA) [3].
Source: International Journal of Cardiology - August 7, 2016 Category: Cardiology Authors: Kudret Aytemir, Adel Aminian, Serkan Asil, U ğur Canpolat, Ergün Barış Kaya, Levent Şahiner, Banu Evranos, Hikmet Yorgun, Necla Özer Source Type: research
New onset atrial fibrillation is associated with elevated Galectin-3 levels
Atrial fibrillation (AF) is the commonest tachyarrhythmia, affecting approximately 30 million people worldwide [1]. The presence of AF is associated with significant increase in cardiovascular mortality and morbidity [1]. In addition, the major complication of AF is stroke due to increased thromboembolic risk engendered by AF. The precise pathogenic mechanisms of AF remain incompletely understood. However, it is thought that active post-inflammatory fibrosis leading to atrial remodeling, resulting in electrical, biochemical as well as structural change within the atria is pivotal in the development of AF.
Source: International Journal of Cardiology - August 7, 2016 Category: Cardiology Authors: D. Chen, N. Procter, V. Goh, S. Liu, S.J. Chua, B. Assadi-Khansari, S. Stewart, J.D. Horowitz, A.L. Sverdlov, D.T. Ngo Source Type: research
Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship
For the prevention of stroke and/or systemic embolism (SSE) in non-valvular atrial fibrillation (NVAF), the four available non-vitamin K-antagonist oral anticoagulants (NOACs) are each marketed in a higher and a lower dose: 150 and 110mg for dabigatran, 20 and 15mg for rivaroxaban, 5 and 2.5mg for apixaban and 60 and 30mg for edoxaban. The lower dose is commonly used with the aim to reduce the patient's exposure to the drug (and its anticoagulant effect), thereby reducing the risk of bleeding. This however, may not always be true, depending on the NOAC used and the characteristics of the patients to whom the NOAC is given.
Source: International Journal of Cardiology - August 10, 2016 Category: Cardiology Authors: Andrea Rubboli, Freek W.A. Verheugt Tags: Correspondence Source Type: research
The C of CHADS: Historical Perspective and Clinical Applications for Anticoagulation in patients with Non Valvular Atrial Fibrillation and Congestive Heart Failure
The risk stratification of patients with coexisting non valvular atrial fibrillation and congestive heart failure, is often a clinical challenge, as the definitions of congestive heart failure in the popular CHADS2 and CHA2DS2VASc scoring systems, and amongst major clinical trials on Warfarin and Novel Oral Anticoagulants (NOAC) have heterogeneity. Available evidence reveals that any heart failure and/or left ventricular systolic dysfunction is associated with higher rates of stroke/systemic embolism and bleeding in patients with non valvular atrial fibrillation compared to patients without heart failure and normal left ventricular function.
Source: International Journal of Cardiology - September 16, 2016 Category: Cardiology Authors: Y Chugh, RT Faillace Tags: Editorial Source Type: research
30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death
Long-term nationwide trends in atrial fibrillation (AF) incidence and 5-year outcomes are rare.
Source: International Journal of Cardiology - September 20, 2016 Category: Cardiology Authors: Morten Schmidt, Sinna Pilgaard Ulrichsen, Lars Pedersen, Hans Erik B øtker, Jens Cosedis Nielsen, Henrik Toft Sørensen Source Type: research
Persistent atrial standstill with coronary and cerebral embolism treated with left atrial appendage closure
Systemic arterial embolism or stroke occurs predominantly in elderly patients with persistent atrial fibrillation. Here we report a young patient with persistent atrial standstill and left atrial appendage thrombus, leading to coronary and cerebral embolic events.
Source: International Journal of Cardiology - September 30, 2016 Category: Cardiology Authors: Zhonghua Sun, Yanmin Zhou, Ding Zhou, Yat-Yin Lam, Yunzhou Huang, Jian Zhang, Yuanlu Chen, Xiangqian Qi Tags: Correspondence Source Type: research
